Patrys Limited · ASX:PAB
Patrys — Investor Presentation (January 2026)
21 slides from Patrys's investor presentation, Jan 28, 2026
Slide 1: Acquisition of Reliis
ASX: PAB Acquisition of Reliis 28 January 2026 patrys.com 1
Slide 2: Safe Harbour Statement
Safe Harbour Statement The following material is for general information purposes only and is not to be relied upon for the making of an investment decision. Any investment in Patrys Limited ACN 123 055 363 (Patrys) is subject to investment risk including the possibility of loss of capital invested
Slide 3: Company Snapshot
Company Snapshot Performance Ordinary Shares Options Rights Opening 340,729,915 - 90,812,025 Consideration Shares 110,000,000 - - Performance Rights - 70,000,000 - Con Note Shares 25,000,000 - - Reliis Facilitation Shares 50,000,000 - - PAB Facilitation Shares 6,666,666 - - TOTAL 532,396,581 70,000,
Slide 4: Board of Directors
Board of Directors Peter Christie Brian Leedman Leanne Kite Dino Cercarelli Dr Anton Uvarov CHAIRMAN DIRECTOR DIRECTOR DIRECTOR DIRECTOR • 25+ years’ accounting and • Biotech entrepreneur with a • Experienced finance, • Healthcare and clinical trial • Extensive healthcare and ASX governance experien
Slide 5: Reliis: Reformulation Approach
Reliis: Reformulation Approach First Indication Clinical stage ~500M Individuals suffering from delirium, a common acute neurocognitive condition biopharmaceutical Lead Product company focused on AQS – Proprietary IV formulation of quetiapine – providing faster, more predictable onset of action, saf
Slide 6: Delirium: Severe & Acute Mental Disturbance
Delirium: Severe & Acute Mental Disturbance Confusion Cognitive Disorientation Decline Altered Thinking & Behaviours Increased Risk of Dementia* 3 Kinds • Withdrawn (Hypoactive) • Mixed • Aggressive (Hyperactive) * Richardson et al., Age and Ageing 2021; 50: 914–920 Investor Presentation| January 20
Slide 7: > US$2 Billion Delirium Market
Delirium Market (Serviceable Market *Est) US Market Estimated Revenue by Segment $387M $1070M# $32M Australian Market Intensive Palliative Aged Care Care Care $85M $150M $11M 30–80%* 22–62%* 15–40%* Global Market $797M $380M $600M Total Serviceable Addressable Market Assumptions: • 31% ICU admission
Slide 8: The Problem: Current Treatment Challenges
The Problem: Current Treatment Challenges Variable Effectiveness No Approved • No approved drug Treatment Low quality data supporting use Significant adverse side-effect treatments profiles • Many drugs used without approval (“OFF- “OFF-LABEL” Quetiapine: Atypical Antipsychotic & Antipsychotic LABEL
Slide 9: Clinical Valuation of Unmet Need
Clinical Valuation of Unmet Need “Dealing with delirium every day is “I worry the patient will hurt themselves exhausting. Most drug therapies just or staff (or me) before we get control. sedate the patient, it's like shooting in the Then I worry I’ll over-sedate them” dark” “Dosing is a nightmare,
Slide 10: Our Solution
Our Solution Administered Intravenously (IV) A novel and Subcutaneously (SC) reformulated injectable format (AQS) Ideally suited to ICU Effectively resolves delirium allowing treatment of underlying cause Also suitable for aged and palliative care Investor Presentation| January 2026 Patrys Limited (
Slide 11: Stage of Development
Stage of Development Favourable injection characteristics A novel pH, Osmolality, GRAS excipients reformulated injectable format Known oral PK characteristics (AQS) for efficacy in delirium Favourable manufacturing characteristics Very stable - Min 2 years stability Known Safety and potential contra
Slide 12: Advantages of Injectable AQS
Advantages of Injectable AQS • Rapid onset of action (1 min v 2h) • 100% bioavailability (all the dose administered) • No impact of patient physiology or metabolism • Customisable dosing control (can be rapidly reversed if required) • Rapid relief from agitation • Improved Safety of staff and patien
Slide 13: Competitive Advantage of AQS
Competitive Advantage of AQS Oral IV IV SL AQS Quetiapine Haloperidol Dexmedetomide Olanzapine Efficacy +++ ++ + + - Speed of activity +++ + + ++ +++ ++ Adverse effects + + +++ ++ ++ Cardiac effects (QTc) – + +++ – ++ Sedation + + ++ +++ ++ Investor Presentation| January 2026 Patrys Limited (ASX:PAB
Slide 14: Clinicians Will Adopt AQS
Clinicians Will Adopt AQS AQS will replace Oral Quetiapine is commonly used for current off label, delirium* ineffective treatments, integrating with Initial Target Product Profile: current workflow • ICU/postoperative delirium. • Multi-professional post-operative workflow Physical therapy, ICU and
Slide 15: Commercialisation: Reformulation Pathway
Commercialisation: Reformulation Pathway Traditional New Drug Development Pathway Drug Drug Phase Phase Phase Post Validation Pre-clinical Regulatory Discovery Formulation 1 2 3 Market 10–15 Years Average Cost $1.2B (US) Accelerated Reformulation Drug Development Pathway Innovative FDA Regulatory pa
Slide 16: Injectable AQS: Fast Track Clinical Development
Injectable AQS: Fast Track Clinical Development Bridging Studies Required 2026 H1 2026 H2 2027 H1-H2 2028 ... • Microdosing in humans plus PBPK modelling and simulation Pre-Study 01 02 03 • Prediction of human dose from human data not animals Activities P0 Exploratory P1/ Bioequivalent Pivotal P2/3
Slide 17: Reformulation Examples
Reformulation Examples In 2024 the FDA approved Comparable Reformulations many (~25) drugs under the Original Reformulated 505(b)(2) reformulation Indication Indication Deal pathway. Chronic pain Acute post operative pain Mallinckrodt management management (IV) $1.4B acquisition (oral) (paracetamol)
Slide 18: Strategic Partner Suggestions
Strategic Partner Suggestions Ideal Partner: Innovative Generic Examples Company: • Teva • A dedicated hospital/acute care • Viatris sales force. Those branching out into new products. • Sandoz • Existing products in CNS, • Mallinckrodt psychiatry, ICU sedation, or • BioXcel Therapeutics anesthesia.
Slide 19: Intellectual Property Protection
Intellectual Property Protection • Provisional Australia patent application Australian Provisional Patent No. 2022901032 No. 2022901032 • Wholly owned by Entered National Phase* Q4 2024 Reliis with no trailing World Intellectual Property Office (WIPO) (PCT/AU2023/050316). obligations • US • EU/UK •
Slide 20: News Flow and Catalysts
News Flow and Catalysts Event Target Date Completion Engineering batch Drug product for Q2 2026 CMC Ethics approval Phase 0 Q2 2026 GMP Clinical batch release Q3 2026 Phase 0 initiation Q3 2026 Phase 0 completion Q4 2026 File provisional patent on final product Q4 2026 FDA pre-IND response Q1 2027 6
Slide 21: Contact
Contact Dr. Anton Uvarov Phone: +61 450 662 770 Email: info@patrys.com Patrys Limited (ASX:PAB) patrys.com Investor Presentation| January 2026